TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00115687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine polacrilex
Study: NCT00616954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-F
Description: ATG-f
Study: NCT01906151

Intervention type: DEVICE
Group type: OTHER
Intervention: SENSIMED Triggerfish®
Description: SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
Study: NCT02998840

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: odorless suspension

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: odorless suspension

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: odorless suspension

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: odorless suspension
Study: NCT04400240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALLS
Description: The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
Study: NCT03424954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EpxOstomy
Description: A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
Study: NCT01500603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdvanceXP Male sling device
Description: Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro-ACT balloon device
Description: Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
Study: NCT04755166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral ridge augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral ridge augmentation
Study: NCT02512601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: Sulodexide (two capsules of Sulodexide 15 mg twice daily).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression therapy
Description: Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable.
Study: NCT02609230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-201
Study: NCT03976362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT02780856

Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging with the Calcivis System
Description: Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
Study: NCT02408003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose.
Study: NCT02959827

Intervention type: DRUG
Intervention: Iodinated contrast agents
Description: Use of iodine contrast agents and doses following the decision of the treating physician.
Study: NCT03349424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
Study: NCT01773551

Intervention type: OTHER
Intervention: Breast Density
Description: Development of a Quantitative Tissue Optical Index of Breast Density
Study: NCT02123238

Intervention type: OTHER
Group type: OTHER
Intervention: bed positioning

Intervention type: OTHER
Group type: OTHER
Intervention: bed positioning
Study: NCT01170455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: nasal intubation with macintosh laryngoscope after general anesthesia induction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blind Intubation Device
Description: nasal intubation using Blind Intubation Device after general anesthesia induction
Study: NCT01518166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: One single dose of 40 mg. Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: One single dose of 20 mg. Tablet
Study: NCT02123238

Intervention type: OTHER
Group type: OTHER
Intervention: bed positioning
Study: NCT02110329

Intervention type: GENETIC
Group type: NO_INTERVENTION
Intervention: evaluation of the recurrence rate according to molecular analysis
Study: NCT04002284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib 12mg p.o. d1-14, 21days/cycle
Study: NCT01518166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: griseofulvin
Description: One single dose of 500 mg. Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: One single dose of 1 mg. Tablet
Study: NCT02192814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg/20 mL)
Description: Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion
Study: NCT01286012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Ferric Pyrophosphate in liquid bicarbonate
Description: Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Conventional liquid bicarbonate
Description: Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythrocyte Stimulating Agent (ESA)
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocyte Stimulating Agent (ESA)
Description: ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous (IV) Iron
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Iron
Description: Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
Study: NCT01453257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored Chemotherapy
Description: Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU
Study: NCT00661622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization
Description: A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
Study: NCT03438175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced communication by brochure, website and posters
Description: Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
Study: NCT04053192

Intervention type: PROCEDURE
Intervention: BAV
Description: BAV

Intervention type: PROCEDURE
Intervention: BAV
Description: BAV

Intervention type: PROCEDURE
Intervention: BAV
Description: BAV

Intervention type: PROCEDURE
Intervention: BAV + TAVR
Description: BAV + TAVR

Intervention type: PROCEDURE
Intervention: BAV + TAVR
Description: BAV + TAVR

Intervention type: PROCEDURE
Intervention: BAV + TAVR
Description: BAV + TAVR

Intervention type: PROCEDURE
Intervention: SAVR
Description: Surgical aortic valve replacement (SAVR)

Intervention type: PROCEDURE
Intervention: SAVR
Description: Surgical aortic valve replacement (SAVR)

Intervention type: PROCEDURE
Intervention: SAVR
Description: Surgical aortic valve replacement (SAVR)
Study: NCT04646798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: standard surgical approaches to repair of fractured elbows

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total elbow arthroplasty
Description: standard surgical approaches to repair of fractured elbows
Study: NCT02987920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Additional medication to perioperative analgesic regimen in Group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Concentrate
Description: Additional medication to perioperative analgesic regimen to Group A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Multimodal analgesic regimen to Group A and Group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Multimodal analgesic regimen to Group A and Group B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Multimodal analgesic regimen to Group A and Group B
Study: NCT01240525

Intervention type: OTHER
Group type: OTHER
Intervention: CD4 DLI
Description: Patients will receive CD4 DLI between day 70 to 115 post transplant

Intervention type: OTHER
Group type: OTHER
Intervention: No DLI
Description: Patients will not receive DLI as trial treatment
Study: NCT04446130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine combined with HAAG Regimen
Description: Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
Study: NCT01124123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: 10 mg endovenous bilastine
Study: NCT01534260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib, vorinostat and bortezomib
Description: Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
Study: NCT04934709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT-sMF
Description: PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
Study: NCT02359045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1400147
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1400147
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000136
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000136
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000137
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D14000137
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova®
Description: Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova®
Description: Treatment D
Study: NCT01077999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC = 2 , weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 , weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2, weekly
Study: NCT03976362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablets
Study: NCT01077999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: panitumumab: 6mg/kg in weeks 1-3-5.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
Study: NCT00035607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa SC
Description: Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa IV
Description: Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
Study: NCT02099344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artegraft
Description: Surgical placement of graft for hemodialysis access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propaten
Description: Surgical placement of graft for hemodialysis access
Study: NCT02821299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngeal transplantation
Description: Laryngeal transplantation
Study: NCT02823574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study: NCT02663466

Intervention type: PROCEDURE
Intervention: erroneous off-midline closures
Description: All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.

Intervention type: PROCEDURE
Intervention: erroneous off-midline closures
Description: All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
Study: NCT04600076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BabyCenter site and the community group
Description: Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
Study: NCT02482194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: autologous transplantation of mesenchymal stem cells in spinal cord injury patients
Study: NCT01588314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: gabapentin 100 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: compounded placebo capsules